All News

"It's actually a very exciting time to be a robotic surgeon," says Ronney Abaza, MD, FACS.

"[A parental leave policy] is something that this generation, both men and women, not only are going to be happy to see, they're going to expect it," says Kari Bailey, MD.

"Bladder cancer is exploding. [It] is exciting, it's changing, and we're just at the start of this," says Jason M. Hafron, MD, CMO.

"When we look at focal therapy in general, the better we're able to see, localize, identify and risk stratify prostate cancers, the better we're able to treat them and offer more personalized and focal treatments," says Arvin George, MD.

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

"We...talked a little bit about BCG-unresponsive disease, which is a really hot topic; a lot of trials and a lot of data are coming there," says Gautam Jayram, MD.

“You have to be balanced in what to embrace vs what not. It is easy to be wowed by new things," said Scott Eggener, MD.

"We found that the new TENACIO pump was able to complete tasks faster and more efficiently compared to the older MS pump," says Justin Lee, MD.

Final completion of the ECLIPSE trial is anticipated for February 2029.

The phase 1/2a SECuRE trial is evaluating the safety and efficacy of 67Cu-SAR-bisPSMA in the treatment of patients with mCRPC.

The sensitivity of 99mTc-sestaMIBI SPECT/CT was 97%, and the specificity was 53.8%.

In total, 33.3% of patients with a VUS also had positive lymph node involvement and required adjuvant ADT compared with only 16.2% of patients who did not have a VUS.

"Together, the data point to the exciting potential for this combination regimen to be used to treat patients with muscle invasive bladder cancer," says Roger Li, MD.

“It is critical that urologists understand when to order germline testing, are comfortable with actually ordering these tests, and integrate medical geneticists when appropriate," says Aditya Bagrodia, MD, FACS.

“Our study is distinguished by long follow-up, out to 12 years, looking at a broad spectrum of key complications," says Joseph M. Unger, PhD.

Overall, 76% of patients with a CD70 TPS of at least 50% achieved a reduction in tumor burden.

The decision was based on an interim readout from the trial, which showed that ONCT-534 did not lead to any clinically meaningful improvement of disease.

At the end of the induction phase, 86% of patients had achieved a complete response.

Patients with high P-CARE scores had an increased risk of any, metastatic, and fatal prostate cancer compared with patients with median P-CARE scores.

The observational LOBSTER study has already enrolled 303 patients and collected 479 samples.

"If you tapped into your emergency fund for any reason this year, it is important to make sure the account is replenished," writes Jeff Witz, CFP.

The revised policy will take effect on January 1, 2025.

In total, the study plans to enroll 84 adult patients across clinical trial sites in the United States and Australia.

“Based on these data, casdatifan has the potential to be a future treatment option for kidney cancer," says Toni K. Choueiri, MD.

The UUI responder rate was 71.8% among those who received SNM and 71.3% among those who received iTNM.

A rapid reduction in E coli in the urine was observed among 10 of 16 evaluable patients at 4 hours following the first treatment.

The decision comes after a pre-specified futility analysis determined that it was unlikely that the study would meet its primary end point.

Anti-tumor activity was observed across all patients with FGFR3-altered metastatic urothelial carcinoma who were treated at the dose levels of 90 mg and higher.